HER2-positive breast cancer and anti-HER2 therapies
Research activity is centered on advanced and metastatic HER2-positive breast cancer, including disease that has progressed after prior trastuzumab-based treatment. The sponsor also funds studies in locally advanced settings and in patients receiving HER2-targeted therapy combined with other systemic approaches.
- Trastuzumab deruxtecan
- Pertuzumab
- HER3-directed therapy
- Anti-HER2 ADCs
These trials include biomarker-linked work in ERBB2 expression and treatment-sensitive subgroups within HER2-positive disease.
Hormone receptor-positive and HER2-negative breast cancer
The sponsor supports research in HR-positive/HER2-negative breast cancer across early, locally advanced, and metastatic stages, with attention to endocrine-resistant disease and high-risk early presentations. Both premenopausal and postmenopausal populations are represented.
- Endocrine resistance
- CDK4/6 inhibitor resistance
- Ribociclib
- Elacestrant
Work in this area also includes operable early disease with residual cancer after neoadjuvant treatment and biologically selected high-risk tumors.
Triple-negative and advanced metastatic breast cancer
Clinical studies extend to triple-negative breast cancer and broader advanced metastatic settings, including patients with unresectable locally advanced disease and those with residual disease after prior chemotherapy. The portfolio reflects interest in difficult-to-treat, later-line breast cancer populations.
- Sacituzumab govitecan
- Patritumab deruxtecan
- Metastatic disease
- Residual disease
Several studies focus on treatment response in heavily pretreated disease and on patients with limited remaining standard options.
Biomarker-driven oncology and precision medicine
The sponsor funds trials that use molecular and functional markers to refine treatment selection in breast cancer and other solid tumors. This includes biomarker-defined groups with BRCA1/2, PALB2, RAD51 alterations, PIK3CA mutation, and immune-related markers such as PD1 expression.
- DNA repair biomarkers
- PI3K/AKT pathway
- Immune checkpoint targeting
- Tumor response biomarkers
These studies link molecular profiling with therapeutic choice in metastatic breast cancer and selected pan-cancer settings.
Early breast cancer and perioperative treatment
Research also covers early-stage breast cancer, including operable disease, neoadjuvant treatment, and post-surgical settings with residual disease. The sponsor’s interests include luminal breast cancer, high-risk early breast cancer, and treatment selection in patients with biologic response after preoperative therapy.
- Neoadjuvant therapy
- Adjuvant endocrine therapy
- Ki67 proliferation
- Operable breast cancer
Studies in this area address both treatment intensification and de-escalation strategies within early breast cancer care.
